CDMO Sterling Pharma Solutions has announced what it called the next phase of a multi-year investment strategy at its site in Dudley, UK. It will spend £10 million by mid-2022 on new process development laboratories and commercial-scale manufacturing equipment to meet growth in demand for small molecule API manufacturing.